Stakeholders prepare for the U.S. Food and Drug Administration's ("FDA") rulemaking effort to "make explicit" that laboratory developed tests ("LDTs") are devices subject to the agency's oversight, reigniting outstanding...more
On April 19, 2021, the Consumer Financial Protection Bureau ("CFPB") invoked its rulemaking authority under the Fair Debt Collection Practices Act to issue an interim final rule requiring debt collectors seeking eviction for...more
The President issued an executive order directing agencies to address the economic impact of COVID-19 by eliminating regulations, providing reopening guidance to businesses, and recognizing that regulatory compliance can be...more
Jones Day partners Donald F. McGahn II and Brett A. Shumate discuss the myriad of litigation, investigatory, reputational, and political risks awaiting businesses as they consider reopening during the pandemic. In this...more
5/13/2020
/ Coronavirus/COVID-19 ,
Critical Infrastructure Sectors ,
Defense Production Act ,
Health and Safety ,
Public Readiness and Emergency Preparedness Act (PREP Act) ,
Re-Opening Guidelines ,
Regulatory Oversight ,
Standard of Care ,
State and Local Government ,
Supply Chain ,
Trump Administration
The Background: Test manufacturers and labs are rushing to offer molecular and antibody tests for the novel coronavirus (COVID-19) to meet huge demand. Meanwhile, regulatory oversight during this national emergency has...more